Results 21 to 30 of about 19,188,679 (307)

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]

, 2007
Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Moosmann, Nicolas, Schulz, Christoph, Laessig, Dorit, Michaely, Henrik Jakob, Heinemann, Volker   +4 more
core   +1 more source

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort

, 2022
Background: Metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by a poor survival rate, which can be improved by systemic treatment. Consensus on the most optimal first- and second-line palliative systemic treatment is lacking.
Creemers, G.J., Creemers, Geert-Jan, Besselink, M.G., Besselink, Marc G., Wilmink, Johanna W., Mohammad, N.H., Dijksterhuis, Willemieke P.M., Dijksterhuis, W.P.M., Wilmink, J.W., Creemers, Geert Jan, Dijksterhuis, Willemieke P. M., van Laarhoven, Hanneke W. M., Pijnappel, E.N., de Vos-Geelen, J., van Laarhoven, Hanneke W.M., Homs, Marjolein Y. V., de Vos-Geelen, Judith, de Groot, J.W.B., de Groot, Jan Willem B., van der Geest, Lydia G., Mohammad, Nadia Haj, van der Geest, L.G., van Laarhoven, H.W.M., Homs, Marjolein Y.V., Homs, M.Y.V., Pijnappel, Esther N.   +25 more
core   +1 more source

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

BMC Cancer, 2021
Background Limited treatment options exist for relapsed advanced lung squamous cell carcinoma (SCC), leading to poor outcomes compared with adenocarcinoma.
You-Yi Chen, Shih-Chieh Chang, Cheng-Yu Chang, Chun-Fu Chang, Yi-Chun Lai, Yu-Feng Wei, Chung-Yu Chen   +6 more
doaj   +1 more source

Dolutegravir for second-line treatment: Programmatic implications of new evidence

Southern African Journal of HIV Medicine, 2022
No abstract available.
Ying Zhao, Gary Maartens, Graeme Meintjes   +2 more
doaj   +1 more source

Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study

BMC Infectious Diseases, 2019
Background Currently, there is limited evidence on the effectiveness of second-line antiretroviral therapy (ART) in sub-Saharan Africa. To address this challenge, outcomes of second-line protease inhibitor (PI) based ART in Rwanda were assessed.
Sabin Nsanzimana, Muhammed Semakula, Vedaste Ndahindwa, Eric Remera, Dieudonne Sebuhoro, Jean Paul Uwizihiwe, Nathan Ford, Marcel Tanner, Steve Kanters, Edward J. Mills, Heiner C. Bucher   +10 more
doaj   +1 more source

Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague

Viruses, 2022
Plague pandemics and outbreaks have killed millions of people during the history of humankind. The disease, caused by the bacteria Yersinia pestis, is currently treated effectively with antibiotics.
Yaron Vagima, David Gur, Moshe Aftalion, Sarit Moses, Yinon Levy, Arik Makovitzki, Tzvi Holtzman, Ziv Oren, Yaniv Segula, Ella Fatelevich, Avital Tidhar, Ayelet Zauberman, Shahar Rotem, Emanuelle Mamroud, Ida Steinberger-Levy   +14 more
doaj   +1 more source

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. [PDF]

, 2014
We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological ...
Awio, P., Munderi, P., Pillay, D., Ndembi, N., Nkurunziza, P., Ndembi, N, Pattery, T, Dunn, DT, van Cauwenberge, A, Gilks, C. F., Gilks, CF, Awio, P, Munderi, P, Nkurunziza, P, Kaleebu, P., Pillay, D, Goodall, RL, DART Virology Group and Trial Teams, Kaleebu, P, Goodall, R. L., Kityo, C., Dunn, D. T., Kityo, C, Pattery, T., van Cauwenberge, A., K. Mataruka, B. Kikaire, M. Nabankkema, H. Grosskurth, P. Khauka, M. Namyalo, C. Kityo, C. Parry, C. F. Gilks, M. Spyer, R. Magala, P. Kaleebu, R. L. Goodall, P. Nkurunziza, N. Ndembi, R. Goodall, A. Zalwango, T. Pattery, L. Generous, P. Awio, D. Dunn, D. Pillay, K. Fadhiru, G. Kabuye, L. Mugarura, G. Nassuna, M. Chirara, M. Katuramur, B. Magambo, J. Nkalubo, R. Massa, A. van Cauwenberge, E. Zalwango, V. Robertson, P. Munderi, D. Yirrell, R. Kasirye, D. M. Gibb, A. Kapaata, D. T. Dunn, D. Nsibambi, F. Lyagoba, T. Musunga, A.L. McCormick, M. Nakazibwe, C. Gilks   +70 more
core   +1 more source

REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE

Медицинский совет, 2017
Angiogenesis   has  become  an  important  target  in  the  treatment  of  solid  tumors  and  anti-angiogenic   agents   are a  promising  approach  to  cancer  therapy.
N. S. Besova, T. A. Titova, V. A. Gorbunova, O. O. Gordeeva, A. A. Tryakin, A. V. Snegovoy, R. Yu. Nasyrova, A. A. Rumyantsev, E. A. Voroshilova, E. V. Artamonova   +9 more
doaj   +1 more source

Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second‐line treatment regimen for unresectable pancreatic cancer: A real‐world analysis

Cancer Medicine, 2022
Background Although second‐line treatment for pancreatic cancer has been proven to have survival benefit, it is not clear which is the most preferred regimen. This study compared the efficacy and safety of modified FOLFIRINOX (mFOLFIRINOX) and sequential
Shun Tezuka, Makoto Ueno, Ritsuko Oishi, Shuhei Nagashima, Yusuke Sano, Kuniyuki Kawano, Satoshi Tanaka, Taito Fukushima, Hiroyuki Asama, Naoki Konno, Satoshi Kobayashi, Manabu Morimoto, Shin Maeda   +12 more
doaj   +1 more source

Consequences of targeted treatments for second-line therapy

Annals of Oncology, 2010
The paradigm for first-line treatment of relapsed or metastatic non-small cell lung cancer (NSCLC) is changing. Large phase III trials demonstrated that, in 2010, we cannot select a therapy without an accurate definition of tumor histology and epidermal growth factor receptor (EGFR) status.
E, De Maio, C, Tibaldi, A, D'Incecco, S, Bursi, C, Barbara, S, Cupini, R, Di Marsico, M, D'Arcangelo, L, Landi, G, Minuti, F, Cappuzzo   +10 more
openaire   +2 more sources